Hypothesis

Chronic low‑level ROS emanating from somatic mtDNA heteroplasmy directly suppresses TET2 activity, leading to focal hypermethylation and loss of accessibility at enhancers governing myeloid differentiation and metabolic programs in young hematopoietic stem cells (HSCs).

Experimental Design

1. Model – Generate inducible, HSC‑specific mito‑mutator mice (PolG D257A) crossed with Vav‑Cre‑ERT2; tamoxifen at 8 weeks induces mtDNA mutagenesis without affecting nuclear DNA.
2. Groups – (a) Wild‑type controls, (b) mito‑mutator + vehicle, (c) mito‑mutator + MitoQ (mitochondria‑targeted antioxidant), (d) mito‑mutator + HSC‑specific TET2 overexpression.
3. Readouts – At 4 weeks post‑induction:
   • mtDNA heteroplasmy load by duplex sequencing.
   • Intracellular ROS (MitoSOX) and NADPH oxidase activity.
   • ATAC‑seq and oxidative bisulfite sequencing (oxBS‑seq) on lineage‑negative Sca‑1⁺c‑Kit⁺ (LSK) cells.
   • Colony‑forming unit (CFU) assays and competitive repopulation to assess functional aging.
4. Rescue Test – Compare chromatin accessibility and methylation patterns between groups (c) and (d) to group (b).

Expected Outcomes

• Mito‑mutant HSCs will show a 2‑3‑fold rise in heteroplasmy, elevated mitochondrial ROS, and a significant reduction in ATAC‑seq signal at enhancers of Ppargc1a, Foxo3, and Gata2 (mirroring the inaccessibility seen in aged HSCs) [3][4].
• oxBS‑seq will reveal increased 5‑mC (but not 5‑hmC) at the same loci, ind

Hypothesis

Senescent endothelial cells release mitochondrial DNA (mtDNA) packaged in extracellular vesicles (EVs). These EVs act as damage‑associated molecular patterns that bind TLR9 on adjacent endothelial cells, triggering NADPH oxidase‑derived ROS production. The ROS surge exacerbates eNOS uncoupling, further lowering NO bioavailability and relieving NO‑mediated suppression of NF‑κB. Consequently, ICAM‑1 transcription is amplified, promoting leukocyte adhesion and propagating a paracrine senescence wave that extends beyond the initially stressed cells.

Mechanistic Rationale

• mtDNA as a DAMP: Oxidative stress in senescent endothelium damages mitochondria, leading to mtDNA release. EVs enriched in mtDNA have been shown to activate innate immune receptors in recipient cells (5).
• TLR9‑ROS link: TLR9 engagement recruits MyD88 and activates TRAF6, which stimulates the NOX2 complex. This pathway has been demonstrated to elevate superoxide in vascular models (6).
• eNOS uncoupling amplification: Increased superoxide scavenges NO and oxidizes tetrahydrobiopterin (BH4), shifting eNOS from a NO‑producing to a superoxide‑producing enzyme (1).
• ICAM‑1 elevation: Reduced NO fails to inhibit NF‑κB nuclear translocation, while ROS act as secondary messengers that enhance IKK activity, driving ICAM‑1 transcription (1, 2).

Hypothesis

Short-term treatment with a NAD+ precursor (nicotinamide riboside) combined with an AMPK activator (metformin) prior to dasatinib+quercetin (D+Q) senolytic exposure will increase the clearance of senescent cells that are resistant to D+Q alone by lowering the NAD+/NADH ratio, activating SIRT1, and shifting the Bcl‑2 family balance toward pro‑apoptotic BH3‑only proteins.

Mechanistic Rationale

Senescent cells display heterogeneity in cell‑cycle arrest status, which correlates with variable sensitivity to senolytics [8]. Resistant subsets often up‑regulate anti‑apoptotic Bcl‑2 and MCL‑1 to survive pro‑apoptotic stress. Restoring NAD+ levels rebalances the NAD+/NADH ratio, enhancing SIRT1 deacetylase activity [5]. SIRT1 deacetylates FOXO3a, promoting transcription of BH3‑only proteins such as BIM and PUMA, which neutralize Bcl‑2/MCL‑1 and facilitate mitochondrial outer‑membrane permeabilization. Parallel AMPK activation (e.g., via metformin) further inhibits mTORC1, reduces protein synthesis, and increases autophagy, creating a metabolic state that diminishes the survival advantage of senescent cells. This dual metabolic priming should lower the threshold for D+Q‑induced BCL‑XL/BCL‑2 inhibition, converting resistant senescent cells into a D+Q‑sensitive phenotype.

Experimental Design

A double‑blind, placebo‑controlled trial in adults aged 65‑80 with elevated circulating p16INK4a (>2‑fold age‑matched median) will test three arms over 12 weeks:

1. D+Q alone – dasatinib 100 mg + quercetin 1000 mg orally for 3 consecutive days every 4 weeks (standard regime

Hypothesis

Aging exacerbates MASLD by inducing a hypoxia‑responsive epigenetic program in zone 3 hepatocytes that elevates labile iron and suppresses cystine uptake, thereby sensitizing these cells to ferroptosis. Pharmacologic or genetic inhibition of HIF‑2α in aged hepatocytes will reduce the Aging Hepatocyte Gene Signature (AHGS), lower ferroptotic death, and attenuate fibrosis independent of direct ferroptosis inhibitors.

Mechanistic Basis

Zone 3 hepatocytes already operate under low oxygen tension, which stabilizes HIF‑2α (not HIF‑1α) in chronic steatosis [2]. HIF‑2α transcriptionally represses ferroportin (FPN1) and upregulates transferrin receptor 1 (TFR1), expanding the intracellular labile iron pool [5]. Simultaneously, HIF‑2α inhibits SLC7A11 (xCT), decreasing cystine import and glutathione synthesis, a key prerequisite for GPX4‑mediated lipid peroxide detoxification [3]. In aged hepatocytes, declining NAD⁺/SIRT1 activity further diminishes deacetylation of HIF‑2α, prolonging its stability [6]. The combined iron overload and antioxidant deficit push lipid peroxidation past the ferroptotic threshold, explaining why ferroptosis inhibitors like ferrostatin‑1 reverse AHGS [1] but do not address the upstream hypoxic signal.

Predictions and Experimental Design

1. Genetic test: Hepatocyte‑speci

Hypothesis

In aged B cells, autophagy is not merely impaired; it is actively suppressed to limit chromatin accessibility and thereby curb excessive somatic hypermutation (SHM) that could generate autoreactive antibodies. This protective restraint comes at the expense of reduced antibody diversity and poorer vaccine responses.

Mechanistic Model

1. mTORC1 Hyperactivation – Persistent nutrient‑sensing signals in aged B cells keep mTORC1 active, leading to ULK1 phosphorylation and inhibition of autophagosome initiation [1].
2. SASP‑Driven NF‑κB/p38MAPK Signaling – Senescent B cells secrete IL‑6 and TNF‑α, activating NF‑κB and p38MAPK pathways that upregulate the autophagy inhibitor Rubicon and phosphorylate TFEB, sequestering it in the cytoplasm [3,4].
3. Chromatin Consequence – Reduced autophagy diminishes lysosomal degradation of damaged mitochondria, lowering ROS but also decreasing nuclear export of histone deacetylases. The resulting hyperacetylated chromatin state would normally promote SHM; however, the concurrent rise in Rubicon‑mediated autophagy block impairs the delivery of LC3‑associated chromatin remodelers needed for controlled AID targeting [5].
4. Outcome – The net effect is a restrained SHM landscape, limiting the generation of high‑affinity but potentially autoreactive clones, while preserving a pool of relatively naïve‑like B cells that avoid autoimmunity.

Predictions and Experimental Tests

• Prediction 1: Pharmacological inhibition of mTORC1 (e.g., rapamycin) or neutralization of SASP cytokines (anti‑IL‑6/TNF‑α) in aged B ce

Hypothesis

Restoring CRAT activity specifically in myeloid immune cells prevents mitochondrial DNA release, suppresses cGAS‑STING‑NF‑κB driven SASP, and thereby slows organismal aging even when systemic carnitine pools remain low.

Rationale

1. Metabolic‑immune coupling – CRAT deficiency creates an acetyl‑CoA/CoA imbalance that hyperacetylates mitochondrial proteins, diminishes SIRT3 deacetylase activity, elevates ROS, and triggers mtDNA efflux into the cytosol [https://onlinelibrary.wiley.com/doi/full/10.1111/acel.14000]. This mtDNA activates cGAS‑STING, culminating in NF‑κB‑mediated SASP and chronic inflammation.
2. Cell‑type specificity – Fibroblast‑specific CRAT loss reproduces skin aging phenotypes, yet myeloid cells are the primary sensors of cytosolic DNA and major SASP producers in aged tissues. If the immune compartment is the effector of the mtDNA‑cGAS‑STING axis, rescuing CRAT there should uncouple metabolic decline from inflammatory aging.
3. Supplementation paradox – Oral L‑carnitine raises plasma carnitine and muscle fat oxidation but fails to lower circulating IL‑6, TNF‑α, or CRP in older adults [https://pmc.ncbi.nlm.nih.gov/articles/PMC5852831/]. This suggests that restoring global carnitine flux is insufficient to normalize the acetyl‑CoA/CoA ratio within immune cell mitochondria, where CRAT activity may be the limiting node.

Novel Mechanistic Insight

CRAT not only buffers acetyl groups but also sustains the NAD⁺‑dependent SIRT3 deacetylase cycle by keeping acetyl‑CoA low. In CRAT‑deficient macrophages, hyperacetylated SIRT3 subs

Hypothesis

Age-related decline in α‑ketoglutarate (AKG) causes succinate accumulation, which inhibits prolyl hydroxylase domain (PHD) enzymes and stabilizes HIF‑1α, driving a pseudohypoxic state that contributes to inflammation and aberrant DNA methylation. Supplementation with AKG reverses this by restoring the AKG/succinate ratio, reactivating PHD‑mediated HIF‑1α hydroxylation and degradation, thereby reducing HIF‑1α‑dependent transcriptional programs and allowing normal TET‑mediated demethylation to proceed. This positions AKG’s anti‑aging effect as a metabolic repair of TCA cycle flux rather than a hormetic stress response or a direct TET cofactor effect alone.

Mechanistic Rationale

• AKG is a competitive inhibitor of succinate at the PHD active site; high succinate/low AKG ratios impair HIF‑1α hydroxylation, leading to its stabilization even under normoxia [1].
• Aging is associated with a ~10‑fold drop in plasma AKG [1], while succinate rises with mitochondrial dysfunction, creating conditions for HIF‑1α accumulation.
• Stabilized HIF‑1α recruits histone deacetylases and DNA methyltransferases to hypoxia‑responsive elements, promoting hypermethylation at specific CpG sites and suppressing TET access [2]
• Restoring AKG lowers succinate, reactivates PHDs, decreases HIF‑1α protein, and reduces HIF‑1α‑driven epigenetic noise, permitting TET enzymes to demethylate targets that were previously blocked.
• The ob

Background

Anti-citrullinated protein antibody (ACPA) positivity precedes clinical rheumatoid arthritis (RA) by years, yet predicting when a seropositive individual will transition to clinical disease remains unsolved. HLA-DR molecules — particularly the shared epitope alleles (SE, HLA-DRB1*04:01, *04:04, *01:01) — present citrullinated peptides to CD4+ T cells, driving the adaptive autoimmune response. However, soluble HLA-DR (sHLA-DR) shed from antigen-presenting cells carries bound peptide cargo that reflects ongoing MHC-II antigen presentation in vivo.

Hypothesis

We hypothesize that serial measurement of soluble HLA-DR complexed with citrullinated peptides (sHLA-DR–citpep) in serum, quantified via immunoprecipitation-mass spectrometry (IP-MS), will reveal a characteristic kinetic inflection — a nonlinear acceleration in sHLA-DR–citpep concentration and citrullinated peptide diversity — 6–18 months before the first clinical joint swelling in ACPA-positive at-risk individuals. This inflection represents the transition from tolerized, low-level citrulline presentation to an amplified, epitope-spreading–driven presentation cascade that commits the immune system to clinical autoimmunity.

Mechanistic Rationale

1. Epitope spreading signature: As tolerance breaks down, citrullinated peptide diversity in sHLA-DR cargo should expand from 1–3 dominant epitopes (e.g., citrullinated vimentin, α-enolase) to 8–15+ epitopes, detectable by tandem MS peptide identification.
2. APC activation amplification: Dendritic cell and macrophage activation in pre-articula

Hypothesis\n\nIn immune‑hot breast tumors, the spatial proximity of MIF‑high cancer cells to CD99‑high macrophages creates immunosuppressive niches that blunt PD‑1/CTLA4 blockade efficacy, independent of overall T‑cell infiltration.\n\n## Mechanistic Rationale\n\n- MIF secreted by cancer cells binds CD99 on stromal macrophages, triggering a shift toward an M2‑like phenotype.\n- These macrophages release IL‑10, TGF‑β and CCL2, which (a) upregulate PD‑L1 on neighboring tumor cells and (b) recruit regulatory T cells, fostering a local immune‑suppressive microdomain.\n- Spatial transcriptomics shows that cytokine gradients decay over ~50 µm; thus only tumor regions within this radius experience heightened checkpoint expression and T‑cell exhaustion.\n- This explains why bulk RNA‑seq detects high PD‑1/CTLA4 (immune‑hot signature) yet TIDE scores remain high: the immunosuppressive signal is spatially restricted and missed by bulk averaging.\n\n## Testable Predictions\n\n1. Multiplexed immunofluorescence or imaging mass cytometry will reveal a positive correlation between the shortest distance from MIF+ cancer cells to CD99+ macrophages and local PD‑L1/MHC‑II ratios within the same tumor section.\n2. Patients whose tumors have >30 % of MIF+ cancer cells within 30 µm of a CD99+ macrophage will exhibit significantly lower objective response rates to anti‑PD‑1/CTLA4 therapy than those with larger intercellular distances, even when overall CD8+ T‑cell density is high.\n3. Pharmacologic blockade of CSF1R (which reduces macrophage survival) or genetic knockdown of MIF in cancer cells

Hypothesis

We hypothesize that sub‑RPE C3 deposition initiates a self‑reinforcing cycle: C3‑mediated opsonization of damaged mitochondria activates microglial phagocytosis, which generates reactive oxygen species (ROS) that further impair mitochondrial function and suppress autophagy flux. The resulting accumulation of defective mitochondria amplifies oxidative stress, promotes additional C3 synthesis by retinal microglia and monocytes, and drives terminal MAC formation, leading to RPE and photoreceptor loss. In the absence of C3, this loop is broken, but the loss of C3‑dependent opsonization shifts microglial clearance toward a pro‑inflammatory phenotype that relies on C5a‑mediated signaling, explaining why CFH−/−.C3−/− mice exhibit worse inflammation than CFH−/− single mutants.

Testable Predictions

1. Mitochondrial ROS as an upstream trigger – In aged wild‑type mice, mitochondrial ROS levels in the sub‑RPE will rise before detectable C3 deposition. Pharmacological scavenging of mitochondria‑targeted ROS (e.g., MitoTEMPO) will delay C3 accumulation and MAC formation.
2. Autophagy flux links C3 to mitochondrial health – Enhancing mitophagy with Urolithin A or overexpressing Parkin in RPE cells will reduce C3‑positive puncta and lower LC3B‑II/I ratios, whereas genetic blockade of autophagy (Atg5 knockdown) will exacerbate C3 deposition even when ROS are scavenged.
3. C3 deficiency redirects microglial activation – In C3−/− retinas, microglia will show increased expression of C5aR1 and pro‑inflammatory cytokines (IL‑1β, TNFα) compared with wild‑type aged

Hypothesis

Oral Lactobacillus strains release extracellular vesicles (EVs) containing GABA and short‑chain fatty acids that directly activate nodose ganglion afferents, producing an immediate vagal efferent burst that accelerates HRV recovery (RMSSD, RSA) following an acute psychological stressor.

Mechanistic Insight

Recent work shows Lactobacillus rhamnosus upregulates GABA receptors and lowers corticosterone [2], while L. paracasei PS23 enhances GABAergic activity [3]. We propose that the anxiolytic signal is not only mediated through downstream neurotransmitter changes in the brain but also through a fast, peripherally restricted pathway: Lactobacillus‑derived EVs cross the intestinal barrier, reach the submucosal plexus, and are taken up by vagal nodose neurons expressing GABA_A and GABAB receptors as well as FFAR2/3 for SCFAs. This triggers rapid depolarization of afferent fibers, increasing solitary tract nucleus firing and enhancing vagal outflow within seconds—reflected in a faster rise of RMSSD post‑stress.

Testable Prediction

In a single‑subject (n=1) crossover trial, administering a dose of L. rhamnosus JB-1 (10^9 CFU) 30 min before a standardized mental arithmetic stressor will produce a significantly shorter HRV recovery time (time to return to baseline RMSSD) compared with placebo, measurable via 5‑minute RMSSD windows. The effect should be abolished by pretreatment with a peripherally acting vagal blocker (e.g., low‑dose intravenous atropine)

Hypothesis

Engineering AAV6 to deliver TFEB under a stress‑inducible promoter (GRP78 or ATF4) will improve healthspan only when skeletal muscle experiences periodic physiological stress (e.g., intermittent fasting or exercise), because TFEB‑driven lysosomal biogenesis will be activated synchronously with autophagy flux, thereby converting a transient siege into a coordinated survival response. Constitutive TFEB expression will fail to extend lifespan and may exacerbate lysosomal overload.

Rationale

The seed idea frames autophagy as a rationing system invoked during chronic nutrient siege, not a constitutive housekeeping program. Supporting this, Beclin‑1‑dependent autophagy is stress‑responsive and dispensable for basal turnover【1】(https://pmc.ncbi.nlm.nih.gov/articles/PMC3242613/), while TFEB overexpression rescues age‑related autophagy‑lysosome deficits【2】(https://www.aging-us.com/article/101144/text). AAV serotype tropism shows AAV6 efficiently transduces skeletal muscle【3】(https://pmc.ncbi.nlm.nih.gov/articles/PMC10000783/). Pathological stress states such as myocardial infarction increase AAV transduction in affected tissue【4】(https://doi.org/10.1101/2024.06.10.597311), suggesting that delivery during stress enhances nuclear entry and expression. High AAV doses exhaust DNA repair, imposing a metabolic burden that can negate benefits【5】(https://doi.org/10.1101/2025.04.22.649920). Longevity effects of autophagy modulation are highly condition‑dependent【6】(https://elifesciences.org/reviewed-preprints/110620v1). Together, these data argue that TFEB should be expre

Hypothesis: Perivascular Fibroblast-Derived Wnt5a Maintains Zona Reticularis Progenitor Niche and Its Age‑Dependent Loss Drives DHEAS Decline

Core proposition With advancing age, perivascular fibroblasts in the adrenal cortex reduce secretion of Wnt5a, a non‑canonical Wnt ligand that sustains zona reticularis (ZR) progenitor proliferation and steroidogenic enzyme expression. This decline uncouples ZR homeostasis from corticotropin (ACTH) signaling, leading to selective atrophy of the ZR while the zona fasciculata (ZF) remains ACTH‑responsive, thereby producing the observed cortisol/DHEAS dissociation.

Mechanistic chain

1. In young adults, perivascular fibroblasts adjacent to the ZR capsule release Wnt5a, which binds ROR2 receptors on ZR progenitor cells, activating β‑catenin‑independent pathways that upregulate CYP17A1 and SULT2A1, the key enzymes for DHEAS synthesis (4).
2. Wnt5a also promotes angiocrine factors (e.g., VEGF‑A) that preserve the microvascular network surrounding the ZR, preventing centripetal rarefaction (6).
3. With age, chronic low‑grade inflammation and elevated glucocorticoids induce fibroblast senescence (↑p16^INK4a^, ↓Wnt5a transcription) (1).
4. Reduced Wnt5a diminishes progenitor proliferation, accelerates ZR atrophy, and lowers DHEAS output, while ACTH‑driven cortisol production in the ZF persists or increases due to preserved

Hypothesis

Chronic mTOR inhibition mimics nutrient scarcity but inadvertently lowers cellular NAD+ levels through AMPK‑driven PARP activation, which diminishes SIRT1 deacetylase activity and permits unchecked DNMT‑mediated promoter methylation of tumor‑suppressor genes in the intestinal field. Concurrent NAD+ repletion rescues SIRT1 function, attenuates methylation drift, and synergizes with rapamycin to reduce both tumor burden and field cancerization.

Mechanistic Rationale

• mTORC1 suppression by rapamycin raises the AMP/ATP ratio, activating AMPK.
• Active AMPK stimulates NAD+‑consuming PARP1 in response to mild mitochondrial stress, decreasing the NAD+/NADH ratio.
• Reduced NAD+ limits SIRT1 activity; SIRT1 normally deacetylates and destabilizes DNMT1 and DNMT3B, keeping their expression low.
• When SIRT1 is inhibited, DNMTs accumulate, leading to hypermethylation of CpG islands in tumor‑suppressor promoters (e.g., SFRP2, TFPI2) across the histologically normal mucosa.
• NAD+ supplementation (e.g., nicotinamide riboside) restores the NAD+ pool, reactivates SIRT1, promotes DNMT turnover, and reverses methylation marks without altering rapamycin’s cytostatic effects.

Testable Predictions

1. In APC^Min/+ mice, rapamycin alone will reduce adenoma number but increase average methylation percentage of SFRP2 and TFPI2 in normal‑appearing colonic crypts compared with untreated controls.
2. Co‑administration of nicotinamide riboside with rapamycin will prevent the rapamycin‑induced rise in methylation and further lower adenoma count relative to rapamycin monotherap

Hypothesis

In senescent endothelial cells, eNOS uncoupling-generated superoxide preferentially nitrates tyrosine residues on ICAM-1, enhancing its binding affinity for leukocyte integrins and retarding its endocytic turnover. This post‑translational stabilization amplifies leukocyte adhesion and transmigration independent of transcriptional upregulation, creating a redox‑driven feed‑forward loop that sustains the senescence‑associated secretory phenotype (SASP) and vascular inflammation.

Mechanistic rationale

• eNOS uncoupling in senescence shifts NO synthesis to superoxide production [eNOS uncoupling and ROS].
• Superoxide reacts with residual NO to form peroxynitrite, a potent nitrating agent that can modify ICAM-1 tyrosine residues, increasing its affinity for Mac‑1 (CD11b/CD18) on neutrophils and monocytes [ICAM-1 upregulation by TNF-α and shear stress].
• Nitrated ICAM-1 resists clathrin‑mediated internalization, prolonging its half‑life at tricellular junctions and sustaining Src/JNK signaling that disrupts VE-cadherin and barrier integrity [Endothelial senescence and SASP]
• Persistent junctional ICAM-1 maintains leukocyte‑derived cytokine delivery (e.g., TNF-α, IL-1β), which further fuels NF‑κB activation and SASP secretion, closing the loop.

Testable predictions

1. Biochemical – Senescent endothelial lysates will show increased tyrosine‑nitrated ICAM-1 detectable by anti‑nitro‑tyrosine

Hypothesis

Chronic NSAID administration abolishes the lifespan‑extending and metabolic benefits observed in TRPV1‑deficient mice by remodeling the gut microbiome in a way that reduces bile‑salt hydrolase (BSH) activity, lowering secondary bile acid production and thereby weakening intestinal FXR signaling.

Mechanistic Basis

• TRPV1 deletion lowers CGRP release from pancreatic sensory neurons, enhancing insulin secretion and promoting longevity [1].
• NSAIDs inhibit cyclooxygenase, altering prostaglandin‑driven gut motility and secretion, which shifts microbial communities toward taxa with low BSH expression (e.g., ↑Blautia, ↓Bifidobacterium) [2].
• Reduced BSH activity decreases conversion of primary to secondary bile acids such as deoxycholic acid, diminishing FXR activation in ileal enterocytes and hepatocytes [3].
• Weak FXR signaling compromises intestinal barrier integrity, increases hepatic inflammation, and promotes cellular senescence, offsetting the metabolic improvements from TRPV1/CGRP modulation.

Thus, the net effect of chronic NSAID use is a microbiome‑mediated "aged" bile acid profile that overrides any direct analgesic benefit.

Testable Predictions

1. Lifespan assay – Old wild‑type mice receiving chronic ibuprofen (or another NSAID) will show no survival advantage compared to untreated controls, whereas TRPV1‑KO mice treated with the same NSAID will lose their extended lifespan relative

Partial reprogramming with transient OSK factors resets epigenetic clocks via TET1/2-dependent DNA demethylation, yet the role of autophagy in this process remains untested. We hypothesize that autophagy is not merely a by‑product of metabolic stress but a necessary supplier of acetyl‑CoA and α‑ketoglutarate (α‑KG) that sustains TET enzyme activity during OSK‑driven demethylation. In this view, autophagy functions as a rationing system that channels intracellular nutrients toward epigenetic remodeling, allowing the cell to survive the siege of reprogramming stress while achieving a youthful methylome.

Testable predictions

1. Genetic blockade of autophagy will impair OSK-induced demethylation. In vivo, inducible OSK expression in aged mice (124 weeks) will be combined with tissue‑specific knockout of essential autophagy genes (Atg5 or Atg7) using Cre‑loxP systems in liver, retina, and kidney. If autophagy is required for TET activity, Atg5/Atg7 loss will significantly blunt the reduction in Horvath multi‑tissue and LUC epigenetic age scores compared with OSK‑only controls, despite comparable OSK expression levels.
2. Metabolite supplementation will rescue the autophagy defect. Providing exogenous α‑KG or acetate (a precursor for acetyl‑CoA) in the drinking water of autophagy‑deficient, OSK‑expressing mice should restore TET activity and partially rescue epigenetic age reversal. This would demonstrate that the key function of autophagy in reprogramming is metabolic support rather than bulk cargo degradation.
3. **Pharmacological inhibition of autophagy phenocopie

Hypothesis

Mitochondrial RNA:DNA hybrids (R-loops) generated from mutant mtDNA transcripts act as the primary danger signal that triggers cGAS-STING-mediated senescence, rather than free mtDNA fragments alone.

Mechanistic Rationale

• mtDNA heteroplasmy increases the likelihood of aberrant transcription, producing RNAs that anneal to the underlying template and form R-loops, especially at sites of replication stressmtDNA heteroplasmy increases....
• These hybrids are exported through VDAC-dependent channels into the cytosol, where their double-stranded RNA:DNA structure is sensed by cGAS as a non‑canonical ligand, leading to STING activation and the senescence-associated secretory phenotype (SASP)cGAS senses RNA:DNA hybrids....
• Because R-loop formation depends on both mutation load and transcriptional activity, a threshold effect explains why some cells with high heteroplasmy remain senescent‑free while others with lower loads undergo premature senescencethreshold effect....

Novel Insight

Targeting mitochondrial RNA processing—specifically boosting mitochondrial RNase H2 activity to degrade the RNA strand of R-loops—should uncouple mutational burden from inflammatory signaling, preserving mitochondrial function while suppressing senescenceRNase H2 suppresses R-loops....

Testable Predictions

1. In cybrid lines carrying defined levels of pathogenic mtDNA m